Department of Science of Life, Institute of Biology, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Department of Pharmacology, School of Medicine, University of Nevada, Reno, NV 89557, USA.
Int J Mol Sci. 2020 Apr 10;21(7):2635. doi: 10.3390/ijms21072635.
Facioscapulohumeral muscular dystrophy (FSHD) is characterized by incomplete penetrance and intra-familial clinical variability. The disease has been associated with the genetic and epigenetic features of the D4Z4 repetitive elements at 4q35. Recently, D4Z4 hypomethylation has been proposed as a reliable marker in the FSHD diagnosis. We exploited the Italian Registry for FSHD, in which FSHD families are classified using the Clinical Comprehensive Evaluation Form (CCEF). A total of 122 index cases showing a classical FSHD phenotype (CCEF, category A) and 110 relatives were selected to test with the receiver operating characteristic (ROC) curve, the diagnostic and predictive value of D4Z4 methylation. Moreover, we performed DNA methylation analysis in selected large families with reduced penetrance characterized by the co-presence of subjects carriers of one D4Z4 reduced allele with no signs of disease or presenting the classic FSHD clinical phenotype. We observed a wide variability in the D4Z4 methylation levels among index cases revealing no association with clinical manifestation or disease severity. By extending the analysis to family members, we revealed the low predictive value of D4Z4 methylation in detecting the affected condition. In view of the variability in D4Z4 methylation profiles observed in our large cohort, we conclude that D4Z4 methylation does not mirror the clinical expression of FSHD. We recommend that measurement of this epigenetic mark must be interpreted with caution in clinical practice.
面肩肱型肌营养不良症(FSHD)的特征是不完全外显率和家族内临床变异性。该疾病与 4q35 处的 D4Z4 重复元件的遗传和表观遗传特征有关。最近,D4Z4 低甲基化已被提议作为 FSHD 诊断的可靠标志物。我们利用意大利 FSHD 登记处,该登记处使用临床综合评估表(CCEF)对 FSHD 家族进行分类。共选择了 122 个表现出典型 FSHD 表型的索引病例(CCEF,类别 A)和 110 个亲属进行接受者操作特征(ROC)曲线分析,以测试 D4Z4 甲基化的诊断和预测价值。此外,我们对具有降低外显率的大型家族进行了 DNA 甲基化分析,这些家族的特征是存在携带一个 D4Z4 减少等位基因的受试者,这些受试者没有疾病迹象或表现出典型的 FSHD 临床表型。我们观察到索引病例中 D4Z4 甲基化水平的广泛变异性,没有发现与临床表现或疾病严重程度有关。通过将分析扩展到家庭成员,我们揭示了 D4Z4 甲基化在检测受影响情况中的低预测价值。鉴于我们大型队列中观察到的 D4Z4 甲基化谱的变异性,我们得出结论,D4Z4 甲基化不能反映 FSHD 的临床表达。我们建议在临床实践中谨慎解释这种表观遗传标记的测量。